Gilead chief O'Day recruits top Genentech researcher as new CMO in the wake of a high-level R&D exodus
Gilead CEO Daniel O’Day has found his new chief medical officer in the top ranks of Roche’s storied biotech subsidiary Genentech, where O’Day had a front-row seat for years as a top executive in the Swiss pharma giant.
O’Day announced this morning that Merdad Parsey, currently the senior VP of early clinical development at Genentech, is stepping over to Gilead as the new CMO at a time the new CEO is reworking the entire top leadership in the wake of a high-level exodus of execs. And in a switch, he says that Parsey will report directly to him, with EVP of research William Lee also making a direct report as well. That move leaves O’Day with a considerable hands-on role in the day-to-day management of R&D.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 63,000+ biopharma pros reading Endpoints daily — and it's free.